|33.23||-0.2700||-0.81%||Vol 1.09M||1Y Perf 84.67%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.04 -0.12%|
|Target Price||38.50||Analyst Rating||Strong Buy 1.00|
|Potential %||15.86||Finscreener Ranking||★★+ 47.16|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 55.76|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 42.70|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||96.67||Earnings Rating||Neutral|
|Market Cap||2.22B||Earnings Date||13th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.89|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||798.81K|
|Avg. Monthly Volume||734.51K|
|Avg. Quarterly Volume||1.56M|
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) stock closed at 33.23 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 1.09M shares and market capitalization of 2.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Crinetics Pharmaceuticals Inc. CEO is R. Scott Struthers.
The one-year performance of Crinetics Pharmaceuticals Inc. stock is 84.67%, while year-to-date (YTD) performance is 81.58%. CRNX stock has a five-year performance of -0.18%. Its 52-week range is between 15.23 and 33.85, which gives CRNX stock a 52-week price range ratio of 96.67%
Crinetics Pharmaceuticals Inc. currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 2.71, a price-to-sale (PS) ratio of 223.36, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -53.26%, a ROC of -55.09% and a ROE of -58.10%. The company’s profit margin is -%, its EBITDA margin is -2 943.10%, and its revenue ttm is $4.03 Million , which makes it $0.07 revenue per share.
Of the last four earnings reports from Crinetics Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Crinetics Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Crinetics Pharmaceuticals Inc. is Strong Buy (1), with a target price of $38.5, which is +15.86% compared to the current price. The earnings rating for Crinetics Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Crinetics Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Crinetics Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.56, ATR14 : 1.51, CCI20 : 115.38, Chaikin Money Flow : 0.11, MACD : 1.28, Money Flow Index : 79.89, ROC : 10.80, RSI : 65.20, STOCH (14,3) : 86.86, STOCH RSI : 0.73, UO : 55.36, Williams %R : -13.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Crinetics Pharmaceuticals Inc. in the last 12-months were: Betz Stephen (Sold 20 714 shares of value $446 028 ), Coelho Rogerio Vivaldi (Buy at a value of $110 300), Dana Pizzuti (Sold 8 212 shares of value $132 624 ), Krasner Alan (Sold 0 shares of value $-84 070 ), Krasner Alan (Sold 7 000 shares of value $210 000 ), Marcus Wilson (Sold 0 shares of value $-278 400 ), Marcus Wilson (Sold 40 922 shares of value $904 903 ), Stephen F. Betz (Sold 20 840 shares of value $400 524 ), Struthers Richard (Sold 0 shares of value $-1 970 600 ), Struthers Richard (Sold 200 000 shares of value $6 111 440 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.